Table 1.

Baseline characteristics of patients with rheumatoid arthritis and matched controls. Data presented as n (%), mean ± SD, or median (interquartile range).

CharacteristicsRAControlsp
Age52.9 ± 12.151.6 ± 10.50.52
Sex, female100 (73.5)54 (68.4)0.44
Race, white120 (88.2)67 (84.8)0.24
Smoking
  Current36 (26.5)7 (8.9)0.002
  Past60 (44.1)28 (35.4)0.25
Family history of early CAD38 (27.9)21 (26.6)0.88
Weight, kg81.8 ± 19.279.2 ± 17.40.35
Height, m1.7 ± 0.11.7 ± 0.10.75
BMI, kg/m229.0 ± 6.328.1 ± 5.50.37
Waist circumference, cm93.9 ± 15.587.7 ± 12.50.003
Hypertension66 (48.5)27 (34.2)0.07
  Systolic BP, mmHg131.1 ± 19.8127.1 ± 16.10.15
  Diastolic BP, mmHg74.2 ± 10.672.2 ± 9.10.24
Use of antihypertensives42 (30.9)17 (21.5)0.11
Use of ACE inhibitors18 (13.6)9 (11.5)0.42
Use of ARB7 (5.1)3 (3.9)0.46
HDL cholesterol, mg/dl47.4 ± 14.147.2 ± 12.40.88
LDL cholesterol, mg/dl113.2 ± 32.6123.4 ± 31.80.02
Triglycerides, mg/dl125.0 ± 68.8111.3 ± 51.50.20
Total cholesterol, mg/dl185.7 ± 35.4192.9 ± 34.40.13
Statin use11 (8.1)7 (8.9)0.82
Serum creatinine, mg/dl0.8 ± 0.20.8 ± 0.20.66
GFR, ml/min per 1.73 m289.6 ± 25.588.0 ±17.70.66
Insulin resistance – HOMA-IR index1.9 ± 1.90.8 ± 0.7< 0.001
Metabolic syndrome39 (28.7)13 (16.5)0.05
Framingham risk score, units11.5 ± 6.110.4 ± 5.40.21
Coronary artery calcium score (Agatston units)0 (0–68.0)0 (0–4.8)0.03
Augmentation index*, %29.9 ± 9.825.6 ± 10.20.01
DAS283.6 ± 1.6N/A
  • * Augmentation index is normalized to a heart rate of 75 bpm. ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blockers; GFR: glomerular filtration rate; BP: blood pressure; CAD: coronary artery disease; BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; DAS28: 28-joint Disease Activity Score; N/A: not applicable.